NCT07365319
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07365319
Title A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (TeLuRide-008)
Acronym TeLuRide-008
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Eikon Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP

Facility Status City State Zip Country Details
Southern Cancer Center, P.C. RECRUITING Daphne Alabama 36526 United States Details
Los Angeles Cancer Network RECRUITING Glendale California 91204 United States Details
Rocky Mountain Cancer Centers, LLP RECRUITING Pueblo Colorado 81103 United States Details
NYU Langone Hospital Long Island RECRUITING Mineola New York 11501 United States Details
NYU Langone Hospital Manhattan RECRUITING New York New York 10016 United States Details
White Plains Hospital RECRUITING White Plains New York 10601 United States Details
Blue Ridge Cancer Center RECRUITING Blacksburg Virginia 24060 United States Details
Virginia Cancer Specialists, PC RECRUITING Fairfax Virginia 22031 United States Details
Shenandoah Oncology P.C. RECRUITING Winchester Virginia 22601 United States Details
Institut Catala D'Oncologia de Girona RECRUITING Girona 17007 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field